Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTANIL vs LIRAGLUTIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Type 2 diabetes mellitus,Adjunct to diet and exercise for glycemic control,Chronic weight management (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity)
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Liraglutide is administered subcutaneously once daily. For type 2 diabetes, start at 0.6 mg daily for one week, then increase to 1.2 mg daily; may further increase to 1.8 mg daily if needed. For weight management (with BMI ≥30 or ≥27 with comorbidities), start at 0.6 mg daily for one week, then escalate weekly by 0.6 mg to a target dose of 3.0 mg daily.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
The terminal elimination half-life of liraglutide after subcutaneous administration is approximately 13 hours, supporting once-daily dosing. The prolonged half-life is due to albumin binding and reduced renal clearance.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Degraded by endogenous peptidases (DPP-4 and neutral endopeptidases); no CYP450 involvement; metabolites are inactive.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Liraglutide is primarily eliminated via degradation into smaller peptides and amino acids, with no significant renal or biliary excretion of the intact drug. Approximately 6% of the dose is excreted unchanged in urine, and less than 5% is excreted in feces as intact liraglutide.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Liraglutide is >98% bound to plasma proteins, primarily albumin. This high binding contributes to its long half-life.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
The volume of distribution after subcutaneous administration is approximately 0.07 L/kg, indicating limited extravascular distribution and primarily remaining in the circulation.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
Subcutaneous: Absolute bioavailability is approximately 55% (range 46-64%). Oral bioavailability is negligible (<1%) due to enzymatic degradation in the gastrointestinal tract.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
No dose adjustment required for mild renal impairment (e GFR ≥60 m L/min/1.73 m²). For moderate impairment (e GFR 30-59), use with caution; limited data. Contraindicated in end-stage renal disease (e GFR <15). No experience in severe impairment (e GFR 15-29); use not recommended.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
No dose adjustment needed for mild hepatic impairment (Child-Pugh class A). Not recommended for moderate to severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Not approved for pediatric patients under 18 years of age for either type 2 diabetes or weight management.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
No dose adjustment based solely on age. Caution in patients ≥75 years due to limited therapeutic experience; monitor renal function and gastrointestinal tolerability.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Risk of thyroid C-cell tumors; contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Acute pancreatitis,Risk of hypoglycemia with insulin secretagogues,Acute kidney injury,Hypersensitivity reactions (e.g., anaphylaxis, angioedema),Heart rate increase,Cholelithiasis and cholecystitis
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Personal or family history of medullary thyroid carcinoma,Multiple Endocrine Neoplasia syndrome type 2,Hypersensitivity to liraglutide or any product components
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
No specific food-drug interactions. Because liraglutide delays gastric emptying, high-fat meals may worsen nausea; advise low-fat meals during titration. Avoid excessive alcohol consumption as it may increase risk of pancreatitis.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Liraglutide is contraindicated in pregnancy. Based on animal studies, it may cause fetal harm. First trimester: avoid use due to potential for malformations. Second and third trimesters: not recommended due to risks of fetal growth restriction and other adverse outcomes.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Liraglutide is excreted in rat milk at a 3-11% ratio relative to maternal plasma; human data unavailable. Not recommended during breastfeeding due to unknown risks to the infant. M/P ratio not determined in humans.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
No dose adjustments established as liraglutide is contraindicated in pregnancy. Physiological changes in pregnancy affect pharmacokinetics, but use is not recommended.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Liraglutide is a GLP-1 receptor agonist with a 13-hour half-life, allowing once-daily dosing. Titrate weekly from 0.6 mg to 1.8 mg for diabetes or up to 3.0 mg for weight management. Monitor for pancreatitis; discontinue if suspected. Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2. Use with caution in renal impairment (e GFR <30). Risk of hypoglycemia when combined with insulin or sulfonylureas; consider dose reduction of these agents. Gastrointestinal side effects (nausea, vomiting, diarrhea) are common; gradual titration mitigates these. Can delay gastric emptying, affecting absorption of oral medications. Effective for glycemic control and weight loss; also reduces cardiovascular risk in T2DM patients with established CVD.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
Inject liraglutide once daily at the same time, regardless of meals, subcutaneously in abdomen, thigh, or upper arm.,Start with 0.6 mg daily for one week, then increase by 0.6 mg weekly to target dose (max 1.8 mg for diabetes, 3.0 mg for weight loss).,If a dose is missed, skip it and take the next dose at the usual time; do not double up.,Common side effects include nausea, vomiting, diarrhea, and constipation; these often improve over time. Eat smaller, low-fat meals to reduce nausea.,Seek medical help immediately if you experience severe abdominal pain (possible pancreatitis) or a lump in the neck, hoarseness, or trouble swallowing (possible thyroid tumor).,Do not use if you or your family have had medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.,Monitor blood glucose regularly if using insulin or sulfonylureas; adjust doses as instructed to avoid low blood sugar.,This medication can cause weight loss; inform your doctor if unintended weight loss occurs.,Store in refrigerator; after first use, can be stored at room temperature for up to 30 days.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTANIL vs LIRAGLUTIDE, answered by our medical review team.
ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. LIRAGLUTIDE is a GLP-1 Receptor Agonist that works by Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTANIL and LIRAGLUTIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. The standard adult dose of LIRAGLUTIDE is: Liraglutide is administered subcutaneously once daily. For type 2 diabetes, start at 0.6 mg daily for one week, then increase to 1.2 mg daily; may further increase to 1.8 mg daily if needed. For weight management (with BMI ≥30 or ≥27 with comorbidities), start at 0.6 mg daily for one week, then escalate weekly by 0.6 mg to a target dose of 3.0 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTANIL and LIRAGLUTIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. LIRAGLUTIDE is classified as Category C. Liraglutide is contraindicated in pregnancy. Based on animal studies, it may cause fetal harm. First trimester: avoid use due to potential for malformations. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.